216 related articles for article (PubMed ID: 9674294)
1. [Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Godoy I; Herrera C; Zapata C; Kunstmann S; Abufhele A; Corbalán R
Rev Med Chil; 1998 Mar; 126(3):259-64. PubMed ID: 9674294
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
3. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
Bassand JP; Berthe C; Bethencourt A; Bolognese L; Wójcik J;
Curr Med Res Opin; 2003; 19(2):107-13. PubMed ID: 12740154
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins in the treatment of unstable angina.
Ageno W; Turpie AG
Minerva Cardioangiol; 2002 Dec; 50(6):643-51. PubMed ID: 12473984
[TBL] [Abstract][Full Text] [Related]
10. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
11. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
[TBL] [Abstract][Full Text] [Related]
12. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
14. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
15. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
[TBL] [Abstract][Full Text] [Related]
16. [Use of heparin in unstable angina and non-Q-wave infarction].
Choussat R; Attali P;
Arch Mal Coeur Vaiss; 2001 Jan; 94(1):62-70. PubMed ID: 11233483
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
White HD
J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
19. [Diltiazem versus intravenous nitroglycerin in the treatment of unstable angina pectoris. A randomized study].
Castro P; Corbalán R; Vergara I; Kunstmann S
Rev Med Chil; 1995 Jul; 123(7):823-9. PubMed ID: 8560112
[TBL] [Abstract][Full Text] [Related]
20. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Demers C
Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
